Heparin-induced thrombocytopenia: Present and future

Journal of Thrombosis and Thrombolysis

Volumn 31, Issue 3, 2011, Pages 353-366

  Cuker, Adam ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Penn Comprehensive Hemophilia and Thrombosis Program   (United States)

Author keywords

Diagnosis; Epidemiology; Heparin induced thrombocytopenia; HIT; Management; Pathophysiology

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; ARGATROBAN; DANAPAROID; DESULFATOHIRUDIN; DEXTRAN 70; DRUG ANTIBODY; FONDAPARINUX; HEPARIN; HEPARIN ANTIBODY; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBOCYTE FACTOR 4; UNCLASSIFIED DRUG; WARFARIN;

AGE DISTRIBUTION; ANTIBODY TITER; BLEEDING; BOLUS INJECTION; CLINICAL EXAMINATION; COMPLEX FORMATION; CONFERENCE PAPER; CONTINUOUS INFUSION; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MONITORING; DRUG RECHALLENGE; FUNCTIONAL ASSAY; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HOST RESISTANCE; HUMAN; IMMUNOASSAY; INCIDENCE; LABORATORY TEST; PATHOPHYSIOLOGY; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; RISK BENEFIT ANALYSIS; SEX RATIO; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOEMBOLISM; THROMBOSIS; TREATMENT DURATION;

ANTICOAGULANTS; AUTOANTIBODIES; BLOOD PLATELETS; HEPARIN; HUMANS; PLATELET ACTIVATION; THROMBOCYTOPENIA;

EID: 79958131485     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-011-0569-6     Document Type: Conference Paper

References (134)

1. Visentin GP, Ford SE, Scott JP, Aster RH (1994) Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 93:81-88 (Pubitemid 24030823)
2. Greinacher A, Potzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C (1994) Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 71:247-251 (Pubitemid 24047336)
3. Kelton JG, Smith JW, Warkentin TE, Hayward CP, Denomme GA, Horsewood P (1994) Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 83:3232-3239 (Pubitemid 24158468)
4. Warkentin TE (2004) History of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A (eds) Heparin-induced thrombocytopenia, 3rd edn. Marcel Dekker, Basel, pp 1-23
5. Martel N, Lee J, Wells PS (2005) Risk for heparin-induced thrombocytopenia with unfractionated and low-molecularweight heparin thromboprophylaxis: a meta-analysis. Blood 106:2710-2715 (Pubitemid 41510744)
6. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG (1995) Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332:1330-1335
7. Girolami B, Prandoni P, Stefani PM, Tanduo C, Sabbion P, Eichler P, Ramon R, Baggio G, Fabris F, Girolami A (2003) The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 101:2955-2999
8. Warkentin TE, Sheppard JA, Sigouin CS, Kohlmann T, Eichler P, Greinacher A (2006) Gender imbalance and risk factors interactions in heparin-induced thrombocytopenia. Blood 108:2937-2941
9. Warkentin TE, Maurer BT, Aster RH (2007) Heparin-induced thrombocytopenia associated with fondaparinux. N Eng J Med 356:2653-2655
10. Rota E, Bazzan M, Fantino G (2008) Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT). Thromb Haemost 99:779-781
11. Salem M, Elrefai S, Shrit MA, Warkentin TE (2010) Fondaparinux thromboprophylaxis-associated heparin-induced thrombocytopenia syndrome complicated by arterial thrombotic stroke. Thromb Haemost 104:1071-1072
12. Ansell J, Slepchuk N Jr, Kumar R, Lopez A, Southard L, Deykin D (1980) Heparin induced thrombocytopenia: a prospective study. Thromb Haemost 43:61-65 (Pubitemid 10150458)
13. Green D, Martin GJ, Shoichet SH, DeBacker N, Bomalaski JS, Lind RN (1984) Thrombocytopenia in a prospective, randomized, double-blind trial of bovine and porcine heparin. Am J Med Sci 288:60-64 (Pubitemid 14015805)
14. Powers PJ, Kelton JC, Carter CJ (1984) Studies on the frequency of heparin-associated thrombocytopenia. Thromb Res 33:439-443 (Pubitemid 14158934)
15. Bailey RT, Ursick JA, Heim KL, Hilleman DE, Reich JW (1986) Heparin-associated thrombocytopenia: a prospective comparison of bovine lung heparin, manufactured by a new process, and porcine intestinal heparin. Drug Intell Clin Pharm 20:374-378 (Pubitemid 16080458)
16. Francis JL, Palmer GJ 3rd, Moroose R, Drexler A (2003) Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. Ann Thorac Surg 75:17-22 (Pubitemid 36099015)
17. Smythe MA, Koerber JM, Mattson JC (2007) The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. Chest 131:1644-1649 (Pubitemid 46981615)
18. Gallus AS, Goodall KT, Beswick W, Chesterman CN (1980) Heparin-associated thrombocytopenia: case report and prospective study. Aust NZ J Med 10:25-31 (Pubitemid 10144147)
19. Malcolm ID, Wigmore TA, Steinbrecher UP (1979) Heparin-associated thrombocytopenia: low frequency in 104 patients treated with heparin of intestinal mucosal origin. Can Med Assoc J 120:1086-1088 (Pubitemid 9172886)
20. Lindhoff-Last E, Nakov R, Misselwitz F, Breddin HK, Bauersachs R (2002) Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular weight heparin. Br J Haematol 118:1137-1142 (Pubitemid 35025982)
21. Bauer TL, Arepally G, Konkle BA, Mestichelli B, Shapiro SS, Cines DB, Poncz M, McNulty S, Amiral J, Hauck WW, Edie RN, Mannion JD (1997) Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 95:1242-1246 (Pubitemid 27097836)
22. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG (2000) Impact of the patient population on the risk of heparin-induced thrombocytopenia. Blood 96:1703-1708 (Pubitemid 30661052)
23. Pouplard C, May MA, Iochmann S, Amiral J, Vissac AM, Marchand M, Gruel Y (1999) Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation 99:2530-2536 (Pubitemid 29228283)
24. Warkentin TE, Roberts RS, Hirsh J, Kelton JG (2003) An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 163:2518-2524 (Pubitemid 37385796)
25. Lubenow N, Hinz P, Thomaschewski S, Lietz T, Vogler M, Ladwig A, Junger M, Nauck M, Schellong S, Wander K, Engel G, Ekkernkamp A, Greinacher A (2010) The severity of trauma determine the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood 115: 1797-1803
26. Crowther MA, Cook DJ, Albert M, Williamson D, Meade M, Granton J, Skrobik Y, Langevin S, Mehta S, Hebert P, Guyatt GH, Geerts W, Rabbat C, Douketis J, Zytaruk N, Sheppard J, Greinacher A, Warkentin TE, Canadian Critical Care Trials Group (2010) The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. J Crit Care 25:287-293
27. Hutchison CA, Dasgupta I (2007) National survey of heparin-induced thrombocytopenia in the haemodialysis population of the UK population. Nephrol Dial Transplant 22:1680-1684 (Pubitemid 47073768)
28. Sanson BJ, Lensing AW, Prins MH, Ginsberg JS, Barkagan ZS, Lavenne-Pardonge E, Brenner B, Dulitzky M, Nielsen JD, Boda Z, Turi S, Mac Gillavry MR, Hamulyak K, Theunissen IM, Hunt BJ, Buller HR (1999) Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 81:668-672 (Pubitemid 29216546)
29. Lepercq J, Conard J, Borel-Derlon A, Darmon JY, Boudignat O, Francoual C, Priollet P, Cohen C, Yvelin N, Schved JF, Tournaire M, Borg JY (2001) Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. BJOG 108:1134-1140 (Pubitemid 33052475)
30. Stein PD, Hull RD, Matta F, Yaekoub AY, Liang J (2009) Incidence of thrombocytopenia in hospitalized patients with venous thromboembolism. Am J Med 122:919-930
31. Burgess JK, Lindeman R, Chesterman CN, Chong BH (1995) Single amino acid mutation of Fc gamma receptor is associated with the development of heparin-induced thrombocytopenia. Br J Haematol 91:761-766
32. Gruel Y, Pouplard C, Lasne D, Magdelaine-Beuzelin C, Charroing C, Watier H (2004) The homozygous FcgammaRIIIa-158 V genotype is a risk factor for heparin-induced thrombocytopenia in patients with antibodies to heparin-platelet factor 4 complexes. Blood 104:2791-2793 (Pubitemid 39434963)
33. Harris K, Nguyen P, Van Cott EM (2008) Platelet PlA2 polymorphism and the risk for thrombosis in heparin-induced thrombocytopenia. Am J Clin Pathol 129:282-286 (Pubitemid 352029319)
34. Carlsson LE, Lubenow N, Blumentritt C, Kempf R, Paperberg S, Schroder W, Eichler P, Herrmann FH, Santoso S, Greinacher A (2003) Platelet receptor and clotting factor polymorphisms as genetic risk factors for thromboembolic complications in heparin-induced thrombocytopenia. Pharmacogenetics 13:253-258 (Pubitemid 36583991)
35. Ziporen L, Li ZQ, Park KS, Sabnekar P, Liu WY, Arepally G, Shoenfeld Y, Kieber-Emmons T, Cines DB, Poncz M (1998) Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia. Blood 92:3250-3259 (Pubitemid 28492332)
36. Li ZQ, Liu W, Park KS, Sachais BS, Arepally GM, Cines DB, Poncz M (2002) Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. Blood 99:1230-1236 (Pubitemid 34547075)
37. Visentin GP, Moghaddam M, Beery SE, McFarland JG, Aster RH (2001) Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia. J Lab Clin Med 138:22-31
38. Newman PM, Chong BH (1999) Further characterization of antibody and antigen in heparin-induced thrombocytopenia. Br J Haematol 107:303-309 (Pubitemid 29530215)
39. Rauova L, Poncz M, McKenzie SE, Reilly MP, Arepally G, Weisel JW, Nagaswami C, Cines DB, Sachais BS (2005) Ultra-large complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 105:131-138 (Pubitemid 40053074)
40. Suh JS, Malik MI, Aster RH, Visentin GP (1997) Characterization of the humoral immune response in heparin-induced thrombocytopenia. Am J Hematol 54:196-201 (Pubitemid 27148257)
41. Untch B, Ahmad S, Jeske WP, Messmore HL, Hoppensteadt DA, Walenga JM, Lietz H, Fareed J (2002) Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. The pathogenic role of IgG. Thromb Res 105:117-123 (Pubitemid 34214926)
42. Reilly MP, Taylor SM, Hartman NK, Arepally GM, Sachais BS, Cines DB, Poncz M, McKenzie SE (2001) Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIa. Blood 98:2442-2447
43. Warkentin TE, Hayward CP, Boshkov LK, Santos AV, Sheppard JA, Bode AP, Kelton JG (1994) Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 84:3691-3699
44. Poole A, Gibbins JM, Turner M, van Vugt MJ, van de Winkle JG, Saito T, Tybulewicz VL, Watson SP (1997) The Fc receptor gamm-chain and the tyrosine kinase Syk are essential for mouse platelets by collagen. EMBO J 16:2333-2341 (Pubitemid 27258634)
45. Blank M, Schoenfeld Y, Tavor S, Praprotnik S, Bofia MC, Weksler B, Walenga MJ, Amiral J, Eldor A (2002) Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int Immunol 14:121-129 (Pubitemid 34144736)
46. Pouplard C, Iochmann S, Renard B, Herault O, Colombat P, Amiral J, Gruel Y (2001) Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 97:3300-3302
47. Arepally GM, Mayer IM (2001) Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood 98:1252-1254
48. Rauova L, Hirsch JD, Greene TK, Zhai L, Hayes VM, Kowalska MA, Cines DB, Poncz M (2010) Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia. Blood 116:5021-5031
49. Rauova L, Zhai L, Kowalska MA, Arepally GM, Cines DB, Poncz M (2006) Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood 107:2346-2353 (Pubitemid 43345554)
50. Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG (2008) Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 6:1304-1312 (Pubitemid 352016309)
51. Cines DB, Rauova L, Arepally G, Reilly MP, McKenzie SE, Sachais BS, Poncz M. Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly. J Clin Apher 22:31-36
52. Arepally GM, Kamei S, Park KS, Kamei K, Li ZQ, Liu W, Siegel DL, Kisiel W, Cines DB, Poncz M (2000) Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies. Blood 95:1533-1540 (Pubitemid 30120810)
53. Warkentin TE (2005) New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest 127:35S-45S
54. Oliveira GB, Crespo EM, Becker RC, Honeycutt EF, Abrams CS, Anstrom KJ, Berger PB, Davidson-Ray LD, Eisenstein EL, Kleiman NS, Moliterno DJ, Moll S, Rice L, Rodgers JE, Steinhubl SR, Tapson VF, Ohman EM, Granger CB, Complications After Thrombocytopenia Caused by Heparin (CATCH) Registry Investigators (2008) Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Int Med 168:94-102
55. Warkentin TE (1998) Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol 35:9-16
56. Warkentin TE (1993) Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 121:535-555
57. Warkentin TE, Kelton JG (2001) Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344:1286-1292 (Pubitemid 32372963)
58. Lubenow N, Kempf R, Eichner A, Eichler P, Carlsson LE, Greinacher A (2002) Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest 122:37-42 (Pubitemid 34754140)
59. Rice L, Attisha WK, Drexler A, Francis JL (2002) Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med 136:210-215 (Pubitemid 34118121)
60. Watkentin TE, Kelton JG (2001) Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 135:502-506
61. Nader ND, Khadra WZ, Reich NT, Bacon DR, Salerno TA, Panos AL (1999) Blood product use in cardiac revascularization: comparison of on- and off-pump techniques. Ann Thorac Surg 68:1640-1643
62. Lillo Le-Louet A, Boutouyrie P, Alhenc-Gelas M, Le Beller C, Gautier I, Aiach M, Lasne D (2004) Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass. J Thromb Haemost 2:1882-1888 (Pubitemid 40192738)
63. Selleng S, Malowsky B, Strobe U, Wessel A, Itterman T, Wollert HG, Warkentin TE, Greinacher A (2010) Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive. J Thromb Haemost 8:30-36
64. Cipolle RJ, Rodvold KA, Seifert R, Clarens R, Ramirez-Lassepas M (1983) Heparin-associated thrombocytopenia: a prospective evaluation of 211 patients. Ther Drug Monit 5:205-211 (Pubitemid 13065408)
65. Greinacher A, Janssens U, Berg G, Bock M, Kwasny H, Kemkes-Matthes B, Eichler P, Volpel H, Potzsch B, Luz M (1999) Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia (HAT) investigators. Circulation 100:587-593 (Pubitemid 29379746)
66. Warkentin TE, Kelton JG (1996) A 14-year study of heparin-induced thrombocytopenia. Am J Med 101:502-507 (Pubitemid 126335970)
67. Nand S, Wong W, Yuen B, Yetter A, Schmulbach E, Gross Fisher S (1997) Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol 56:12-16 (Pubitemid 27398052)
68. Hong AP, Cook DJ, Sigouin CS, Warkentin TE (2003) Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood 101:3049-3051 (Pubitemid 36857994)
69. Meyer-Lindenberg A, Quenzel EM, Bierhoff E, Wolff H, Schindler E, Biniek R (1997) Fatal cerebral venous sinus thrombosis in heparin-induced thrombocytopenia. Eur Neurol 37:191-192 (Pubitemid 27152075)
70. Ernest D, Fisher MM (1991) Heparin-induced thrombocytopaenia complicated by bilateral adrenal haemorrhage. Intensive Care Med 17:238-240
71. LaMonte MP, Brown PM, Hurstin MJ (2004) Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Crit Care Med 32:976-980 (Pubitemid 38471518)
72. Benhamou AC, Gruel Y, Barsotti J, Castellani L, Marchand M, Guerois C, Leclerc MH, Delahousse B, Griguer P, Leroy J (1985) The white clot syndrome or heparin associated thrombocytopenia and thrombosis (WCS or HATT) (26 cases). Int Angiol 4:303-310 (Pubitemid 16203494)
73. Hall AV, Clark WF, Parbtani A (1992) Heparin-induced thrombocytopenia in renal failure. Clin Nephrol 38:86-89
74. Lipton ME, Gould D (1992) Case report: heparin-induced thrombocytopenia - a complication presenting to the vascular radiologist. Clin Radiol 45:137-138
75. Warkentin TE, Greinacher A (2009) Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes. Expert Opin Drug Saf 8:129-144
76. Warkentin TE, Hirte DW, Anderson DR, Wilson WE, O'Connell GJ, Lo RC (1994) Transient global amnesia associated with acute heparin-induced thrombocytopenia. Am J Med 97:489-491 (Pubitemid 24345602)
77. Warkentin TE (1996) Heparin-induced skin lesion. Br J Haematol 92:494-497
78. Schinderwolf M, Kroll H, Ackermann H, Garbaraviciene J, Kaufmann R, Boehncke WH, Ludwig RJ, Lindhoff-Last E (2010) Heparin-induced non-necrotizing skin lesions: rarely associated with heparin-induced thrombocytopenia. J Thromb Haemost 8:1486-1491
79. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A (2006) Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 4:759-765
80. Cuker A, Arepally G, Crowther MA, Rice L, Datko F, Hook K, Propert KJ, Kuter DJ, Ortel TL, Konkle BA, Cines DB (2010) The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost 8:2642-2650
81. Messmore HL, Fabbrini N, Bird ML, Choudhury AM, Cerejo M, Prechel M, Jeske WP, Siddiqui A, Thethi I, Wehrmacher WH, Walenga JM (2010) Simple scoring system for the early management of heparin-induced thrombocytopenia. Clin Appl Thromb Hemost. doi:10.1076/029610387126
82. Pouplard C, Gueret P, Fouassier M, Ternisien C, Trossaert M, Regina S, Gruel Y (2007) Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 5:1373-1379 (Pubitemid 46965362)
83. Bryant A, Low J, Austin S, Joseph JE (2008) Timely diagnosis and management of heparin-induced thrombocytopenia in a frequent request, low incidence single centre using clinical 4T's score and particle gel immunoassay. Br J Haematol 143:721-726
84. Denys B, Stove V, Philippe J, Devreese K (2008) A clinical-laboratory approach contributing to a rapid and reliable diagnosis of heparin-induced thrombocytopenia. Thromb Res 123:137-145
85. Amiral J (1999) Antigens involved in heparin-induced thrombocytopenia. Semin Hematol 36:7-11
86. Pouplard C, Amiral J, Borg JY, Laporte-Simitsidis S, Delahousse B, Gruel Y (1999) Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 111:700-706 (Pubitemid 29200959)
87. Lo GK, Sigouin CS, Warkentin TE (2007) What is the potential for overdiagnosis of heparin-induced thrombocytopenia? Am J Hematol 82:1037-1043
88. Martin-Toutain I, Settegrana C, Ankri A (2009) High levels of heparin-platelet factor 4 antibodies in patients with pseudothrombocytopenia: risk of misdiagnosis. J Thromb Haemost 7:1416-1418
89. Pauzner R, Greinacher A, Selleng K, Althaus K, Shenkman B, Seligsohn U (2009) False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Thromb Haemost 7:1070-1074
90. Zwicker JI, Uhl L, Huang WY, Shaz BH, Bauer KA (2005) Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2:2133-2137
91. Bakchoul T, Giptner A, Najaoui A, Bein G, Santoso S, Sachs UJ (2009) Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 7:1260-1265
92. Juhl D, Eichler P, Lubenow N, Strobel U, Wessel A, Greinacher A (2006) Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol 76:420-426
93. Warkentin TE, Sheppard JA, Moore JC, Moore KM, Sigouin CS, Kelton JG (2005) Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med 146:341-346 (Pubitemid 41712020)
94. Cuker A, Ortel TL (2009) ASH evidence-based guidelines: is the IgG-specific anti-PF4/heparin ELISA superior to the polyspecific ELISA in the laboratory diagnosis of HIT? Hematology Am Soc Hematol Educ Program 250-252
95. Whitlatch NL, Kong DF, Metjian AD, Arepally GM, Ortel TL (2010) Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia. Blood 116:1761-1766
96. Meyer O, Salama A, Pittet N, Schwind P (1999) Rapid detection of heparin-induced platelet antibodies with particle gel immunoassay (ID-HPF4). Lancet 354:1525-1526 (Pubitemid 29502110)
97. Sheridan D, Carter C, Kelton JG (1986) A diagnostic test for heparin-induced thrombocytopenia. Blood 67:27-30 (Pubitemid 16167006)
98. Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C (1991) A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 66:734-736
99. Fratantoni JC, Pollet R, Gralnick HR (1975) Heparin-induced thrombocytopenia: confirmation of diagnosis with in vitro methods. Blood 45:395-401
100. Lee DH, Warkentin TE, Denomme GA, Hayward CP, Kelton JG (1996) A diagnostic test for heparin-induced thrombocytopenia: detection of platelet microparticles using flow cytometry. Br J Haematol 95:724-731 (Pubitemid 26423379)
101. Jy W, Mao WW, Horstman LL, Valant PA, Ahn YS (1999) A flow cytometric assay of platelet activation marker P-selectin (CD62P) distinguishes heparin-induced thrombocytopenia (HIT) from HIT with thrombosis (HITT). Thromb Haemost 82:1255-1259
102. Tomer A (1997) A sensitive and specific functional flow cytometric assay for the diagnosis of heparin-induced thrombocytopenia. Br J Haematol 98:648-656
103. Warkentin TE (2002) Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Arch Pathol Lab Med 126:1415-1423
104. Price EA, Hayward CP, Moffat KA, Moore JC, Warkentin TE, Zehnder JL (2007) Laboratory testing for heparin-induced thrombocytopenia is inconsistent in North America: a survey of North American specialized coagulation laboratories. Thromb Haemost 98:1357-1361 (Pubitemid 350239110)
105. Arepally GM, Ortel TL (2006) Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 355:809-817
106. Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF (1999) Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 106:629-635 (Pubitemid 29279299)
107. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M (2000) Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 96:846-851 (Pubitemid 30616845)
108. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG, Argatroban-915 Investigators (2003) Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 163:1849-1856 (Pubitemid 36960936)
109. Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, Bartholomew J, Sham R, Lerner RG, Zeigler ZR, Rustagi PK, Jang IK, Rifkin SD, Moran J, Hursting MJ, Kelton JG, ARG-911 Study Investigators (2001) Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103:1838-1843 (Pubitemid 32328395)
110. Lewis BE, Wallis DE, Hursting MJ, Levine RL, Leya F (2006) Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest 129:1407-1416 (Pubitemid 43894967)
111. Warkentin TE, Greinacher A, Koster A, Lincoff AM, American College of Chest Physicians (2008) Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:340S-380S
112. Beiderlinden M, Treschan TA, Görlinger K, Peters J (2007) Argatroban anticoagulation in critically ill patients. Ann Pharmacother 41:749-754 (Pubitemid 46752654)
113. Greinacher A, Völpel H, Janssens U, Hach-Wunderle V, Kemkes-Matthes B, Eichler P, Mueller-Velten HG, Pötzsch B (1999) Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 99:73-80 (Pubitemid 29035960)
114. Lubenow N, Eichler P, Lietz T, Greinacher A, Group Hit Investigators (2005) Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 3:2428-2436 (Pubitemid 41727158)
115. Tardy B, Lecompte T, Boelhen F, Tardy-Poncet B, Elalamy I, Morange P, Gruel Y, Wolf M, François D, Racadot E, Camarasa P, Blouch MT, Nguyen F, Doubine S, Dutrillaux F, Alhenc-Gelas M, Martin-Toutain I, Bauters A, Ffrench P, de Maistre E, Grunebaum L, Mouton C, Huisse MG, Gouault-Heilmann M, Lucke V, GEHT-HIT Study Group (2006) Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood 108:1492-1496 (Pubitemid 44316113)
116. Cardenas GA, Deitcher SR (2005) Risk of anaphylaxis after reexposure to intravenous lepirudin in patients with current or past heparin-induced thrombocytopenia. Mayo Clin Proc 80:491-493 (Pubitemid 40471380)
117. Grubb KJ, Salehi P, Chedrawy EG (2010) Bivalirudin: alternative anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. Recent Pat Cardiovasc Drug Discov 5:20-24
118. Kiser TH, Fish DN (2006) Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharmacotherapy 26:452-460
119. Boyce SW, Bandyk DF, Bartholomew JR, Frame JN, Rice L (2011) A randomized, open-label pilot study comparing desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis: PREVENT-HIT study. Am J Ther 18:14-22
120. Chong BH, Gallus AS, Cade JF, Magnani H, Manoharan A, Oldmeadow M, Arthur C, Rickard K, Gallo J, Lloyd J, Seshadri P, Chesterman CN, Australian HIT Study Group (2001) Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study. Thromb Haemost 86:1170-1175 (Pubitemid 33064563)
121. Farner B, Eichler P, Kroll H, Greinacher A (2001) A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 85:947-949
122. Magnani HN, Gallus A (2006) Heparin-induced thrombocytopenia (HIT). A report of 1, 478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost 95:967-981
123. Warkentin TE (2010) Agents for the treatment of heparin-induced thrombocytopenia. Hematol Oncol Clin North Am 24:755-775
124. Warkentin TE, Elavathil LJ, Hayward CP, Johnston MA, Russett JI, Kelton JG (1997) The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Int Med 127:804-812 (Pubitemid 27465548)
125. Srinivasan AF, Rice L, Bartholomew JR, Rangaswamy C, La Perna L, Thompson JE, Murphy S, Baker KR (2004) Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Int Med 164:66-70 (Pubitemid 38067390)
126. Sheth SB, DiCicco RA, Hursting MJ, Montague T, Jorkasky DK (2001) Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost 85:435-440 (Pubitemid 32233014)
127. Harder S, Graff J, Klinkhardt U, von Hentig N, Walenga JM, Watanabe H, Osakabe M, Breddin HK (2004) Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time. Thromb Haemost 91:1137-1145 (Pubitemid 38821270)
128. Babcock RB, Dumper CW, Scharfman WB (1976) Heparin-induced immune thrombocytopenia. N Engl J Med 295:237-241
129. Cimo PL, Moake JL, Weinger RS, Ben-Menachem YB, Khalil KG (1979) Heparin-induced thrombocytopenia: association with a platelet aggregating factor and arterial thromboses. Am J Hematol 6:125-133 (Pubitemid 9223320)
130. Refaai MA, Chuang C, Menegus M, Blumberg N, Francis CW (2010) Outcomes after platelet transfusion in patients with heparin-induced thrombocytopenia. J Thromb Haemost 8:1419-1421
131. Pötzsch B, Klövekorn WP, Madlener K (2000) Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med 343:515
132. Selleng S, Haneya A, Hirt S, Selleng K, Schmid C, Greinacher A (2008) Management of anticoagulation in patients with sub-acute heparin-induced thrombocytopenia scheduled for heart transplantation. Blood 112:4027
133. Gruel Y, Lang M, Darnige L, Pacouret G, Dreyfus X, Leroy J, Charbonnier B (1990) Fatal effect of re-exposure to heparin after previous heparin-associated thrombocytopenia and thrombosis. Lancet 336:1077-1078 (Pubitemid 20366399)
134. Reilly MP, Sinha U, André P, Taylor SM, Pak Y, Deguzman FR, Nanda N, Pandey A, Stolla M, Bergmeier W, McKenzie SE (2010) PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model. Blood. doi:10.1182/blood-2010-03-274969